GLAND.NS
GLAND.NS
INE068V01023
GLAND PHARMA LIMITED
Loading chart...

Company Profile

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Related stocks

ALKEM.NS
ALKEM.NS • India
ALKEM LABORATORIES LTD.
5,279 INR
6.52B USD 1Y -4.4%
AJANTPHARM.NS
AJANTPHARM.NS • India
AJANTA PHARMA LIMITED
3,410.1 INR
4.4B USD 1Y +40.8%
GLENMARK.NS
GLENMARK.NS • India
GLENMARK PHARMACEUTICALS
2,293 INR
6.69B USD 1Y +13.6%
MANKIND.NS
MANKIND.NS • India
MANKIND PHARMA LIMITED
2,368.5 INR
10.11B USD 1Y -3.1%
IPCALAB.NS
IPCALAB.NS • India
IPCA LABORATORIES LTD
1,915.4 INR
5.02B USD 1Y +43%
ABBOTINDIA.NS
ABBOTINDIA.NS • India
ABBOTT INDIA LIMITED
26,000 INR
5.71B USD 1Y -14.5%
PPLPHARMA.NS
PPLPHARMA.NS • India
PIRAMAL PHARMA LIMITED
196.88 INR
2.7B USD 1Y -0.4%
WOCKPHARMA.NS
WOCKPHARMA.NS • India
WOCKHARDT LIMITED
1,996.4 INR
3.35B USD 1Y +42.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
36.7% p.a.
Max Drawdown (5Y)
-77.5%
Sharpe Ratio (5Y)
-0.19
Beta Factor
0.58
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -77.5% in the extended horizon.
ende